Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

NCT04174677 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Stopped due to no enrollment

Conditions

Highly Sensitized Patients on Waiting List for Kidney Transplantation

Interventions

DRUG: Inebilizumab
DRUG: VIB4920
DRUG: Inebilzumab+VIB4920

Sponsor

Amgen